Understanding Hypertrophic Cardiomyopathy: From Disease Mechanisms to Clinical Management - Episode 8

Invasive Treatment Options in Hypertrophic Cardiomyopathy

Published on: April 15, 2026

Martin S. Maron, MD, Florian Rader, MD, Mariko Harper, MD, Viet Le, DMSc, PA-C

Learn when cardiac myosin inhibitors suffice and when myectomy or alcohol ablation fits, with shared decisions at expert HCM centers.

EP. 1: Diagnosing Hypertrophic Cardiomyopathy: Challenges and Gaps in Clinical Practice

EP. 2: Recognizing and Classifying Obstructive Hypertrophic Cardiomyopathy

EP. 3: The Importance of Early Diagnosis and Treatment in Obstructive HCM

EP. 4: Monitoring Treatment Response and Advancing Therapy in Obstructive HCM

EP. 5: Advancing Cardiac Myosin Inhibitor Therapy: Evidence, Monitoring, and Clinical Integration

EP. 6: Differentiating Cardiac Myosin Inhibitors: Clinical Considerations and Drug Interactions

EP. 7: Insights from the MAPLE Trial: Clinical Implications for oHCM Management

Now Viewing

EP. 8: Invasive Treatment Options in Hypertrophic Cardiomyopathy

In the final episode, Invasive Treatment Options in Hypertrophic Cardiomyopathy, the panelists explored the following critical question:

What is the role of invasive procedures for hypertrophic cardiomyopathy?

Led by the moderator, the experts examine invasive procedures, which play a critical role in the management of hypertrophic cardiomyopathy (HCM) for patients who remain symptomatic despite optimal medical therapy. Septal myectomy and alcohol septal ablation are the primary interventions used to reduce left ventricular outflow tract obstruction and improve symptoms such as dyspnea, chest pain, and syncope. These procedures are typically considered for patients with severe obstruction or functional limitations, and careful patient selection is essential to optimize outcomes. When performed by experienced centers, invasive interventions can significantly improve quality of life, functional capacity, and long-term prognosis in patients with obstructive HCM.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this HCP Live Peer Exchange series on hypertrophic cardiomyopathy. Please subscribe to our newsletter for information on upcoming video series.